ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer von Goetze, Thorsten Oliver, Kochen, Lisa, Vortmeyer, Doerthe, Al-Batran, Salah-Eddin, Habibzada, Timorshah, Brunner, Marius, Ettrich, Thomas Jens, Gonzalez-Carmona, Maria A, Kohne, Claus-Henning, Modest, Dominik Paul

Volltext

ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer von Goetze, Thorsten, Eickhoff, Regina, Pons, Miriam, Kochen, Lisa, Vortmeyer, Doerthe, Al-Batran, Salah-Eddin, Habibzade, Timursah, Adler, Marius, Gonzalez-Carmona, Maria A, Ettrich, Thomas Jens, Koehne, Claus-Henning, Pink, Daniel, van Boemmel, Florian, Pession, Ursula, Wehler, Thomas, Modest, Dominik Paul

Volltext